Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACH-0144471 proof-of-mechanism study in low C3 C3G or IC-MPGN
2016-003525-42Phase 2Completed
- Sponsor
- Achillion Pharmaceuticals
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of danicopan in Complement 3 glomerulopathy (C3G) and Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), sponsored by Achillion Pharmaceuticals. Primary endpoint: Increase in C3 levels relative to baseline. Started Oct 2017; status: completed.
02
Drugs
danicopan
03
Conditions
Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on 2016-003525-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003525-42.